Announcement On Approval For Maa Of Allogeneic Ips Cell-Derived Dopaminergic Neural Progenitor Cell Product "Amchepry" In Japan
06/03/2026 24:22
March 6 (Reuters) - Sumitomo Pharma Co Ltd 4506.T: SUMITOMO PHARMA CO LTD - ANNOUNCEMENT ON APPROVAL FOR MAA OF ALLOGENEIC IPS CELL-DERIVED DOPAMINERGIC NEURAL PROGENITOR CELL PRODUCT "AMCHEPRY" IN JAPAN Source text: ID:nTSof8cd9b Further company coverage: 4506.T
Recent news on Sumitomo Pharma
See all newsSumitomo Pharma America Announces First Patient Receives Treatment In Phase 1/2A Study For Investigational Therapy Dsp-3077 For Retinitis Pigmentosa
Regarding A Report Concerning Sumitomo Pharma ( Company's Views On Gcr August 7 Report)
Brief: Sumitomo Pharma - Gotham City Research's August 3 Report Contains Numerous Statements That Are Clearly Inconsistent With Facts
Brief: Gotham City Research Holds Short Positions In Sumitomo Chemical And Sumitomo Pharmaceutical
Table: Sumitomo Pharma -Q1 group results (IFRS)